La catena delle opzioni mostra i dati chiave delle opzioni azionarie di PROCEPT BioRobotics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per PROCEPT BioRobotics..

PROCEPT BioRobotics (NASDAQ:PRCT) Azioni, Catena delle Opzioni

PROCEPT BioRobotics

PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System,, image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. The company's assets are based in the United States. Its revenue is generated from sales of the AquaBeam Robotic System and the accompanying single-use disposable handpieces.

Long Ideas

News

Markets

Media

Trading Ideas

PRCT

Jim Cramer elogia Target per il suo rendimento del 3% e risultati finanziari eccellenti: ecco perché è un&#39;opportunità imperdibile!

Jim Cramer elogia questo titolo: &#34;Il rendimento del 3% è fantastico!&#34;

PROCEPT BioRobotics Corporation - Common Stock

PROCEPT BioRobotics Corp

Golden Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDEN#NASDAQ">GDEN</a>) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.10 by 80 percent. This is a 200 percent increase over earnings of $0.06 per share from the same period last year. The company reported quarterly sales of $161.23 million which missed the analyst consensus estimate of $162.25 million by 0.63 percent. This is a 37.44 percent decrease over sales of $257.73 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

GDEN

Golden Entertainment Q3 EPS $0.18 Beats $0.10 Estimate, Sales $161.23M Miss $162.25M Estimate

aTyr Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATYR#NASDAQ">ATYR</a>) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.22) by 4.55 percent.

ATYR

aTyr Pharma Q3 2024 GAAP EPS $(0.23) Misses $(0.22) Estimate

Spyre Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRE#NASDAQ">SYRE</a>) reported quarterly losses of $(1.36) per share which missed the analyst consensus estimate of $(0.83) by 63.86 percent. This is a 85.44 percent increase over losses of $(9.34) per share from the same period last year.

SYRE

Spyre Therapeutics Q3 EPS $(1.36) Misses $(0.83) Estimate

Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) raises FY2024 Adj EPS guidance from $0.08-0.12 to $0.12-0.14 vs $0.10 analyst estimate. Narrows FY2024 sales outlook from $835.00 million-845.00 million to $837.00 million-843.00 million vs $841.44 million estimate.

Guidance

MYGN

Myriad Genetics Raises FY2024 Adj EPS Guidance from $0.08-0.12 to $0.12-0.14 vs $0.10 Est; Narrows FY2024 Sales Guidance from $835.00M-845.00M to $837.00M-843.00M vs $841.44M Est

WIIM

LCUT

Lifetime Brands shares are trading lower after the company reported worse-than-expected Q3 financial results and lowered its FY24 guidance and Q4 EPS guidance.

SLDP

Solid Power Continues To Expect 2024 Revenue Of $16M - $20M, Est $19.783M

HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.17) by 11.76 percent.

BEAT

HeartBeam Q3 2024 GAAP EPS $(0.19) Misses $(0.17) Estimate

US Global Investors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GROW#NASDAQ">GROW</a>) reported quarterly earnings of $0.02 per share. This is a 300 percent increase over losses of $(0.01) per share from the same period last year. The company reported $2.16 million in sales this quarter. This is a 31.15 percent decrease over sales of $3.13 million the same period last year.

GROW

US Global Investors Q1 EPS $0.02 Up From $(0.01) YoY, Sales $2.16M Down From $3.13M YoY

Innovex International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INVX#NYSE">INVX</a>) reported quarterly earnings of $0.25 per share which met the analyst consensus estimate. This is a 47.92 percent decrease over earnings of $0.48 per share from the same period last year. The company reported quarterly sales of $151.82 million which beat the analyst consensus estimate of $135.00 million by 12.46 percent. This is a 9.15 percent increase over sales of $139.09 million the same period last year.

INVX

Innovex International Q3 Adj $0.25, Inline, Sales $151.82M Beat $135.00M Estimate

Eventbrite (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EB#NYSE">EB</a>) sees Q4 sales of $74.000 million-77.000 million vs $75.47 million estimate.

Eventbrite Sees Q4 Sales $74.000M-77.000M vs $75.47M Est

Tectonic Therapeutic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECX#NASDAQ">TECX</a>) reported quarterly losses of $(1.20) per share which missed the analyst consensus estimate of $(0.84) by 42.86 percent.

TECX

Tectonic Therapeutic Q3 2024 GAAP EPS $(1.20) Misses $(0.84) Estimate

Li-Cycle Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LICY#NYSE">LICY</a>) reported quarterly earnings of $2.15 per share which beat the analyst consensus estimate of $(1.32) by 262.88 percent. This is a 241.45 percent increase over losses of $(1.52) per share from the same period last year. The company reported quarterly sales of $8.40 million which beat the analyst consensus estimate of $6.98 million by 20.34 percent. This is a 78.72 percent increase over sales of $4.70 million the same period last year.

LICY

Li-Cycle Holdings Q3 EPS $2.15 Beats $(1.32) Estimate, Sales $8.40M Beat $6.98M Estimate

Definitive Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DH#NASDAQ">DH</a>) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $0.08 by 25 percent. This is a 11.11 percent increase over earnings of $0.09 per share from the same period last year. The company reported quarterly sales of $62.70 million which beat the analyst consensus estimate of $61.72 million by 1.58 percent. This is a 4.02 percent decrease over sales of $65.33 million the same period last year.

Definitive Healthcare Q3 Adj $0.10 Beats $0.08 Estimate, Sales $62.70M Beat $61.72M Estimate

MeridianLink (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLNK#NYSE">MLNK</a>) reported quarterly earnings of $0.06 per share which missed the analyst consensus estimate of $0.08 by 25 percent. The company reported quarterly sales of $80.369 million which beat the analyst consensus estimate of $79.969 million by 0.50 percent. This is a 5.07 percent increase over sales of $76.488 million the same period last year.

MLNK

MeridianLink Q3 2024 Adj. EPS $0.06 Misses $0.08 Estimate, Sales $80.369M Beat $79.969M Estimate

Boundless Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLD#NASDAQ">BOLD</a>) reported quarterly losses of $(0.74) per share which beat the analyst consensus estimate of $(0.82) by 9.76 percent.

BOLD

Boundless Bio Q3 2024 GAAP EPS $(0.74) Beats $(0.82) Estimate

Sports betting and iGaming company DraftKings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) reported third-quarter financial results<a href="https://www.benzinga.com/earnings"> after market close Thursday.</a>
Here are the key highlights.
What Happened: DraftKings reported third-quarter revenue of $1.095 billion, up 39% year-over-year. The revenue total missed a Street consensus estimate of $1.112 billion according to data <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110724&amp;t=be2bearmibe3na1">from Benzinga Pro.</a>
The company said revenue growth came from strong customer engagement, the acquisition of new customers, the launch in new territories, and the impact of the acquisition of Jackpocket, which closed in May.
The company reported a loss of 17 cents per share, which beat a Street consensus estimate of a loss of 42 cents per share.
Monthly unique payers (MUP) were 3.6 million in the third quarter, up 55% year-over-year. Excluding the impact of the Jackpocket acquisition, monthly unique payers would have been up 27% year-over-year.
The average revenue per MUP was $103 in the third quarter, down 10% year over year. The lower revenue per payer was due to the Jackpocket acquisition. Excluding the Jackpocket acquisition, the average revenue per MUP was 8% higher year over year.
"DraftKings delivered strong performance in the third quarter with the return of NFL and college football," DraftKings CEO Jason Robins said.
DraftKings was live for mobile sports betting in 25 states and Washington D.C., representing 49% of the U.S. population in the third quarter. The company is also live with iGaming in five states and live for both sportsbook and iGaming in Ontario, Canada.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41792879/draftkings-q3-earnings-highlights-nfl-in-focus-will-missouri-legalization-factor-in">DraftKings Q3 Earnings Preview: NFL In Focus, Will Missouri Legalization Factor Into Guidance?</a>
What's Next: The company lowered its fiscal year 2024 revenue guidance from a range of $5.05 billion to $5.25 billion to a new range of $4.85 billion to $4.95 billion due to customer-friendly sport outcomes in the fourth quarter, which comes with the NFL season having several weeks of favorable outcomes for bettors.
Analysts expect the company to report revenue of $5.14 billion for the full fiscal year, according to data from Benzinga Pro.
The company also revised its 2024 adjusted EBITDA guidance from a range of $340 million to $420 million to a new range of $240 million to $280 million.
DraftKings introduced fiscal year 2025 revenue guidance for the first time, with a range of $6.2 billion to $6.6 billion expected. The company also said it expects 2025 adjusted EBITDA to be in a range of $900 million to $1.0 billion, reaffirming guidance from August.
"With major sports converging on the calendar, we are well-positioned to build on this momentum as we further enhance our top-ranked sportsbook app with additional live betting features and exciting new NBA markets," Robins said. "Our focus remains on driving sustainable revenue growth and profitability in 2025 and beyond."
The company's 2024 and 2025 guidance includes all existing mobile sports betting and iGaming markets and Jackpocket, but does not include any pending state launches.
Missouri legalized sports betting on Election Day 2024 and DraftKings expects to launch its sportsbook in the state pending approval. The company also expects to launch its sportsbook in Puerto Rico, which is pending approval.
DKNG Price Action: DraftKings stock is down 5% to $37.00 in after-hours trading Thursday, versus a 52-week trading range of $28.69 to $49.57.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/politics/24/11/41725070/draftkings-offers-10k-in-prizes-for-2024-election-predictions-harris-trump-swing-state-performan">DraftKings Offers $10K In Prizes For 2024 Election Predictions: Harris, Trump Swing State Performance Among Key Questions</a></li>
</ul>
Photo: Shutterstock

Sports Betting

Movers

DKNG

DraftKings Q3 Highlights: Revenue Miss, 2024 Guidance Trim, First 2025 Outlook, CEO Reaffirms Focus On 'Sustainable Revenue Growth'

QRHC

Quest Resources shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results.

Eventbrite (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EB#NYSE">EB</a>) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.13) by 69.23 percent. This is a 60 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $77.80 million which beat the analyst consensus estimate of $75.83 million by 2.60 percent. This is a 4.59 percent decrease over sales of $81.54 million the same period last year.

Eventbrite Q3 EPS $(0.04) Beats $(0.13) Estimate, Sales $77.80M Beat $75.83M Estimate

Arlo Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARLO#NYSE">ARLO</a>) is looking for Q4 Adj EPS of $0.07-0.13 vs $0.11 analyst estimate. sees sales of $116.000 million-126.000 million vs $138.94 million estimate.

ARLO

Arlo Technologies Sees Q4 Adj EPS $0.07-0.13 vs $0.11 Est; Sees Sales $116.000M-126.000M vs $138.94M Est

Lucid Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) reported third-quarter financial results after the market close on Thursday. Here&#8217;s a look at the key metrics from the <a href="https://www.benzinga.com/pressreleases/24/11/n41823730/lucid-announces-third-quarter-2024-financial-results">electric vehicle company&#8217;s quarter</a>.
Q3 Earnings: Lucid reported third-quarter revenue of $200.04 million, beating the&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus estimate</a>&nbsp;of $197.97 million, according to <a href="http://pro.benzinga.com" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>. The EV company reported an adjusted quarterly loss of 28 cents per share, beating analyst estimates for a loss of 30 cents per share.
Lucid said it produced 1,805 vehicles in the third quarter and delivered 2,781.&nbsp;The company ended the quarter with approximately $5.16 billion in total liquidity.
&#8220;Our momentum continues with our third consecutive quarter of record deliveries,&#8221; said&nbsp;Peter Rawlinson, CEO and CTO of Lucid.
 &#8220;Additionally, today we are delighted to open the order book for the much-anticipated Lucid Gravity SUV, a landmark product, which remains on track for start of production this year. Furthermore, our recent capital raise of approximately&nbsp;$1.75&nbsp;billion serves to further secure the future of the company by extending its financial runway well into 2026.&#8221;
Related Link: <a href="https://www.benzinga.com/news/24/11/41781921/what-does-trumps-victory-mean-for-ev-giant-tesla-and-the-big-3-automakers">What Does Trump&#8217;s Victory Mean For EV Giant Tesla And The Big 3 Automakers?</a>
Outlook: Lucid said it remains on track to produce approximately 9,000 vehicles in 2024.
The company announced Thursday morning that its&nbsp;Gravity Grand Touring&nbsp;SUV became available to order. Lucid expects production to start at the end of the year.
&#8220;We continue to see improvements to gross margin performance as our cost reduction efforts are gaining momentum,&#8221; said&nbsp;Gagan Dhingra, interim CFO and principal accounting officer at Lucid.&nbsp;
Management will hold a conference call to further discuss the company&#8217;s quarterly results at 5:30 p.m. ET.
LCID Price Action: <a href="https://www.benzinga.com/quote/LCID" target="_blank" rel="noreferrer noopener">Lucid shares</a> were up 8.09% in after-hours, trading at $ 2.39 at the time of publication, according to <a href="http://pro.benzinga.com" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: Courtesy of Lucid.

After-Hours Center

LCID

Lucid Q3 Earnings: Revenue Beat, EPS Beat, On Track To Produce 9K Vehicles In 2024

Biggest stock movers Monday: DJT, crypto stocks, and more

PROCEPT BioRobotics Corporation (PRCT) Q3 2024 Earnings Call Transcript

Josh Jennings, an analyst from TD Cowen, maintained the Buy rating on PROCEPT BioRobotics (PRCT – Research Report). The associated price target rem...

Strong Financial Performance and Growth Potential Drive Buy Rating for PROCEPT BioRobotics

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Boeing (BA) will offer 90M shares of c...

Boeing to offer 90M common shares, Philips reports mixed Q3: Morning Buzz

PROCEPT BioRobotics announces proposed offering of common stock

Procept BioRobotics (PRCT) announced the commencement of an underwritten public offering of $175M of shares of its common stock. A selling stockhol...

Procept BioRobotics announces $175M common stock offering

In a report released yesterday, Ryan Zimmerman from BTIG maintained a Hold rating on PROCEPT BioRobotics (PRCT – Research Report). The company's sh...

BTIG Remains a Hold on PROCEPT BioRobotics (PRCT)

PROCEPT BioRobotics (PRCT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mike Kratky ...

Strong Future Potential and Resilience: PROCEPT BioRobotics as a Compelling Hypergrowth MedTech Story

The deal priced below last closing price of $96.69. BofA, Piper Sandler and Morgan Stanley are acting as joint book running managers for the offeri...

Procept BioRobotics 1.92M share Spot Secondary priced at $91.00

Truist raised the firm's price target on Procept BioRobotics (PRCT) to $105 from $95 and keeps a Buy rating on the shares. After a "strong" Q3 earn...

Comments

PROCEPT BioRobotics

PROCEPT BioRobotics (PRCT) Opzioni

PROCEPT BioRobotics (NASDAQ:PRCT) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO